From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
The company highlighted continued demand strength and pricing resilience despite global disruptions
The new facility marks Align’s first manufacturing presence in India and its fourth globally
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
NGI will deliver full end-to-end workflows using both EpiFinder cNUC and EpiFinder GenomePro
The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
Subscribe To Our Newsletter & Stay Updated
